pld118 has been researched along with Candidiasis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacher, J; Groll, AH; Kelaher, AM; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ | 2 |
| Ergovic, G; Galic, T; Geschke, U; Hasenoehrl, A; Marsic, N; Mittendorf, J; Schmidt, A; Schoenfeld, W; Skerlev, M | 1 |
3 other study(ies) available for pld118 and Candidiasis
| Article | Year |
|---|---|
Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Candidiasis, Oral; Cycloleucine; Drug Resistance, Fungal; Enzyme Inhibitors; Esophageal Diseases; Female; Fluconazole; Half-Life; Immunosuppression Therapy; Isoleucine-tRNA Ligase; Rabbits | 2004 |
Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Culture Media; Cycloleucine; Female; Immunosuppression Therapy; Isoleucine-tRNA Ligase; Kidney; Liver; Neutropenia; Rabbits; Spleen | 2005 |
In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Cycloleucine; Drug Interactions; Hydrogen-Ion Concentration; Isoleucine; Male; Mice; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Temperature | 2006 |